Neoadjuvant sintilimab combined with gemcitabine and cisplatin (GP) for muscle-invasive bladder cancer (MIBC) patients followed by selective bladder sparing surgery

被引：0
|
作者：
Tong, Z. [1 ]
Fu, G. [2 ]
Zhou, F. [2 ]
Liu, X. [3 ]
Xue, X. [4 ]
Zhang, H. [1 ]
Wang, Y. [2 ]
Zhu, X. [1 ]
Gao, Y. [1 ]
Liu, L. [1 ]
Bao, X. [1 ]
Zheng, Y. [1 ]
Fang, W. [1 ]
Zhao, P. [1 ]
Jin, B. [2 ]
机构：
[1] Zhejiang Univ, Dept Med Oncol, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China
[2] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Urol, Hangzhou, Peoples R China
[3] Zhejiang Univ, Dept Pathol, Affiliated Hosp 1, Hangzhou, Peoples R China
[4] Zhejiang Univ, Dept Radiol, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1024
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2375P
引用
下载
收藏
页码：S1210 / S1210
页数：1
相关论文
共 50 条
  • [1] A phase II study of toripalimab combined with gemcitabine-cisplatin as neoadjuvant therapy for patients with muscle-invasive bladder cancer (MIBC)
    Xu, Abai
    Xu, Peng
    Chen, Chunxiao
    Liu, Zhe
    Jiang, Ning
    Bi, Enguang
    Cao, Manming
    Chen, BinShen
    Liu, Chunxiao
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Neoadjuvant Gemcitabine Plus Cisplatin for Muscle-invasive Bladder Cancer
    Kaneko, Gou
    Kikuchi, Eiji
    Matsumoto, Kazuhiro
    Obata, Jun
    Nakamura, So
    Miyajima, Akira
    Oya, Mototsugu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (07) : 908 - 914
  • [3] Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
    Sung, Hyun Hwan
    Kim, Hana
    Kim, Ryul
    Kim, Chan Kyo
    Kwon, Ghee Young
    Park, Won
    Song, Wan
    Jeong, Byong Chang
    Park, Se Hoon
    INVESTIGATIVE AND CLINICAL UROLOGY, 2022, 63 (02) : 168 - 174
  • [4] Bladder Preservation by Neoadjuvant Chemotherapy followed by Concurrent Chemoradiotherapy with Gemcitabine in Muscle Invasive Bladder Cancer (MIBC)
    Anandadas, C.
    Thompson, C.
    Sanderson, B.
    Lyons, J.
    Stratford, J.
    Logue, J. P.
    CLINICAL ONCOLOGY, 2013, 25 (04) : E69 - E69
  • [5] Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer
    Narayan, Vivek
    Mamtani, Ronac
    Keefe, Stephen
    Guzzo, Thomas
    Malkowicz, S. Bruce
    Vaughn, David J.
    CANCER RESEARCH AND TREATMENT, 2016, 48 (03): : 1084 - 1091
  • [6] BLADDER-SPARING SURGERY (BSS) FOR MUSCLE-INVASIVE BLADDER CANCER (MIBC) AFTER COMPLETE RESPONSE TO NEOADJUVANT CHEMOTHERAPY (NAC)
    Herr, Harry
    JOURNAL OF UROLOGY, 2020, 203 : E1084 - E1084
  • [7] Is neoadjuvant chemotherapy with gemcitabine plus cisplatin beneficial in patients with muscle-invasive bladder cancer?
    Yafi, Faysal A.
    Kassouf, Wassim
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (06) : 747 - 752
  • [8] Phase II trial of neoadjuvant gemcitabine (G) and cisplatin (C) with sunitinib in patients (pts) with muscle-invasive bladder cancer (MIBC)
    Balar, Arjun Vasant
    Iyer, Gopa
    Apolo, Andrea Borghese
    Regazzi, Ashley Marie
    Garcia-Grossman, Ilana Rebecca
    Pendse, Deepa
    Ostrovnaya, Irina
    Chou, Joanne F.
    Bochner, Bernard
    Dalbagni, Guido
    Herr, Harry W.
    Milowsky, Matthew I.
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Biomarker Exploration for neoadjuvant chemotherapy with gemcitabine combined with cisplatin in muscle-invasive bladder cancer.
    Wang, Kun
    Chen, Xusheng
    Zhang, Zhenting
    Hu, Hailong
    Zhang, Aili
    Wang, Xin
    Chen, Lijun
    Liu, Zhizhong
    Yue, Changjiu
    Zhang, Xueying
    Zhang, Menghuan
    Yao, Xin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16556 - E16556
  • [10] Neoadjuvant nivolumab, gemcitabine and cisplatin in muscle-invasive bladder cancer: Study update
    Gupta, Shilpa
    Weight, Christopher J.
    Agarwal, Neeraj
    Gupta, Sumati
    Konety, Badrinath
    Gibb, Ewan
    Davicioni, Elai
    Thyagarajan, Bharat
    Sonpavde, Guru
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
12345